J Korean Ophthalmol Soc > Volume 57(9); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(9):1422-1429.
DOI: https://doi.org/10.3341/jkos.2016.57.9.1422    Published online September 15, 2016.
Risk Factors and Incidence of Elevated Intraocular Pressure after Dexamethasone Intravitreal Implant.
Hyo Cheol Lim, Sung Who Park, Ji Eun Lee, Soo Jin Kim, Ji Woong Lee
1Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea. glaucoma@pnu.ac.kr
2Department of Ophthalmology, Maryknoll Medical Center, Busan, Korea.
3Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
유리체강내 덱사메타존 임플란트 삽입술 후 안압 상승의 발생률과 위험인자
임효철1⋅박성후1⋅이지은1⋅김수진2⋅이지웅1,3
부산대학교 의과대학 안과학교실1, 메리놀병원 안과2, 부산대학교병원 의생명연구원3
Correspondence:  Ji Woong Lee,
Email: glaucoma@pnu.ac.kr
Received: 17 December 2015   • Revised: 15 June 2016   • Accepted: 22 August 2016
Abstract
PURPOSE
To report the incidence of intraocular pressure (IOP) elevation and identify the risk factors of IOP elevation after intravitreal dexamethasone 0.7 mg (Ozurdex®, Allergan, Irvine, CA, USA) implant. METHODS: A total of 86 eyes of 79 patients who underwent intravitreal dexamethasone implantation and who were followed for ≥ 3 months were included in the present study. IOP elevation was defined as a pressure > 21 mm Hg at some time during follow-up. RESULTS: Twenty-nine eyes (33.7%) had an IOP > 21 mm Hg after dexamethasone intravitreal implant. The incidence of IOP elevation increased rapidly at 2–3 months after dexamethasone intravitreal implant. The Kaplan-Meier estimated incidence of IOP elevation was 25.6 ± 4.7% (mean ± standard error) at 81 days. Cox multivariate analysis showed the significant risk factors of IOP elevation to be age < 55 years (p = 0.045), baseline IOP ≥ 15 mm Hg (p < 0.001), and history of intraocular surgery (p = 0.039). CONCLUSIONS: This study demonstrates the incidence of IOP elevation to be 33.7% and describes the risk factors associated with IOP elevation. Clinicians should be cautious regarding the possibility of IOP elevation after intravitreal dexamethasone implant, especially in the presence of identified risk factors.
Key Words: Intraocular pressure elevation;Intravitreal dexamethasone implant;Risk factor


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next